Ionis Pharmaceuticals, Inc
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Show More...
-
Website http://www.ionispharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 33.51 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.62 -0.85 -0.65 -0.55 -0.33 -0.74 -0.5 0.15 2.07 2.08 1.11 Dividends USD Payout Ratio % * Shares Mil 99.0 100.0 101.0 111.0 118.0 120.0 121.0 126.0 134.0 143.0 142.0 Book Value Per Share * USD 2.46 1.87 1.8 3.45 2.91 2.04 1.14 2.46 5.15 9.52 9.76 Free Cash Flow Per Share * USD -0.82 -1.28 -0.03 0.94 -0.74 0.97 -1.11 0.76 3.7 1.07 Return on Assets % -10.14 -16.38 -12.71 -8.71 -4.32 -9.23 -9.26 0.86 13.88 10.05 5.53 Financial Leverage (Average) 2.25 2.83 2.99 2.24 3.71 4.76 9.16 4.0 2.55 2.2 2.27 Return on Equity % -22.84 -40.77 -36.97 -21.61 -12.26 -38.5 -57.64 4.49 40.16 23.54 12.76 Return on Invested Capital % -15.53 -19.13 -11.73 -8.43 -3.48 -9.48 -9.23 5.27 23.51 17.16 10.38 Interest Coverage -3.62 -4.07 -2.53 -2.44 -1.45 -1.39 -1.16 0.48 -0.7 8.11 4.39 Current Ratio 4.56 4.73 5.7 7.52 7.25 5.62 5.96 5.2 7.87 9.97 9.91 Quick Ratio 4.47 4.61 5.5 7.36 7.06 5.48 5.8 4.83 7.48 9.39 9.35 Debt/Equity 0.61 1.26 1.21 0.6 1.76 2.35 5.9 1.83 0.6 0.53 0.58